Thermo Fisher Scientific – Sponsored Content

Sponsored Content

Rapid Lung NGS means you and your patients don’t have to wait

The Hope:

Targeted, cancer genomic profile guided cancer therapy is improving patients’ outcomes, as was shown among others in the Integra study. Patients treated in first-line based on their genomic profile have a 22% higher probability of survival two years from diagnosis1. And as the number of biomarkers associated with targeted treatments keeps increasing (it is expected to be 21 just in NSCLC already in 20252), there is more hope for cancer patients.

The Gaps:

But there are still gaps in a process of providing oncologists with the genomic profile data in time. These gaps are hindering patients’ access to the treatments they could potentially benefit from1,3.

The Solution:

Based on the published data and experiences from many leading cancer centres, there is an emerging solution – Rapid Lung NGS

  • In house, close to the patients, and fast, so you get the complete, potentially actionable biomarker results in time, to guide the first-line therapy
  • and tissue saving, so even small biopsies or cytological specimens can be analysed, and the number of potential re-biopsies is limited to a minimum Learn how Rapid

Lung NGS works in cancer centers and community hospitals around the world for the benefit of NSCLC patients. And ask your pathologist about rapid lung NGS

  • 1. Choksi et al., ESMO 2022
  • 2. Perspective: Accessing Innovation at the Point of Care with Genomic Profiling, Aug 11, 2022, By F. Hoffmann-La Roche Ltd.
  • 3. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer, Sadik et al; JCO Precis Oncol 6: e2200246. © 2022 by American Society of Clinical Oncology